 Ovarian Cancer: Does the approach for BRCA testing make a meaningful difference for patients?

Ovarian Cancer: Does the approach for BRCA testing make a difference for meaningful patients? 

Dr. Vail is the director of the clinical molecular pathology laboratory at Cedars-Sinai Medical Center. The laboratory has a full suite of molecular diagnostic assays, encompassing viral, genetic and oncology testing. Dr. Vail’s academic focus is on the effective utilization of genomic biomarkers, especially those provided by NGS, in the clinical setting and provider outreach and education.

In this session, Dr. Eric Vail addresses the value of knowing the BRCA status of ovarian cancer patients in their disease journey. He discusses the relevance of tests that cover somatic as well as germline BRCA variants for consideration of PARPi therapy for BRCAm patients.